Endoscopic Hemostatic and Sedative Treatment of Esophageal and Gastric Variceal Bleeding

• Status: Recruiting
• Trial end date: 2022-12-30
• Target enrollment: 0
• Participant gender: All

Summary

Remazolam besylate was used for sedation during endoscopic hemostasis in patients with esophageal and gastric varices rupture and bleeding in liver cirrhosis. The onset time, recovery time and incidence of adverse reactions were observed.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Renmin Hospital of Wuhan University
• Treatments: Propofol

Criteria

Inclusion Criteria:

• Patients diagnosed with bleeding from ruptured esophageal and gastric varices

• Endoscopic hemostatic treatment was performed

• Body Mass Index(BMI)18～28kg/m2

Exclusion Criteria:

• History or evidence of increased risk of sedation/anesthesia;

• Pregnant and lactating women;

• Have participated in other drug trials within 30 days prior to enrollment;

• those with contraindications to propofol, opioids and their remedies;

• Unwilling to sign informed consent.